The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Payment partnership with Klarna

19 Jun 2023 07:00

RNS Number : 0551D
Cellular Goods PLC
19 June 2023
 

Press release

 

19 June 2023

 

Cellular Goods PLC

 

("Cellular Goods" or "the Company")

 

Payment partnership with Klarna

 

Cellular Goods (LSE: CBX) a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, is pleased to announce that it has signed an agreement with Klarna Bank AB ("Klarna"), a Swedish provider of online financial services, to bring Klarna's buy now, pay later (BNPL) services to Cellular Goods' ecommerce website.

 

Through the partnership consumers buying products on www.cellular-goods.com can choose to split payment across three equal instalments or can choose to defer payment for up to 30 days with zero interest and no additional fees. The new payment options will be available to all customers in the United Kingdom.

 

Cellular Goods believes that offering flexible purchase options will support increased sales and open the Company's products up to new audiences.

 

Demand for buy now, pay later payment services has surged among all age groups in the UK and is popular with shoppers across Cellular Goods' target demographics. While the age group using BNPL services most frequently is 25-34-year-olds, the fastest-growing group of BNPL users in the UK is now comprised of older and more affluent customers in the 45 and above age cohort (Source: Experian, 2023).

 

Darcy Taylor, chairman and interim CEO, commented: "The partnership with Klarna is an important improvement to our ecommerce offering and responds to a growing consumer trend. Providing our customers with a range of flexible payment methods enhances their shopping experience and expands our reach to new audiences."

 

For further information please contact:

 

Cellular Goods

Darcy Taylor

Chairman and interim CEO

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

First Sentinel Corporate Finance

Corporate Broker & Advisor

Brian Stockbridge

 

+44 7876 888 011

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods develops and markets premium quality skincare and wellness products based on proprietary formulations incorporating biosynthetic lab-made cannabinoids. Our branded products are efficacy-led and research-backed and available online in the UK and US. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.

 

About Klarna:

Since 2005 Klarna has been on a mission to revolutionize the retail banking industry. With over 150 million global active users and 2 million transactions per day, Klarna is meeting the changing demands of consumers by saving them time and money while helping them be informed and in control. Over 500,000 global retail partners, including H&M, Saks, Sephora, Macys, IKEA, Expedia Group, and Nike have integrated Klarna's innovative technology to deliver a seamless shopping experience online and in-store. Klarna has over 5,000 employees and is active in 45 markets. For more information, visit Klarna.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEASKKFDXDEFA
Date   Source Headline
23rd Dec 20227:00 amRNSTR-1: Standard notification of major holdings
23rd Dec 20227:00 amRNSCellular Goods Annual Results
23rd Nov 20226:16 pmRNSTR-1: Standard notification of major holdings
2nd Nov 202210:34 amRNSTR-1: Standard notification of major holdings
24th Oct 20227:00 amRNSProducts launch on Debenhams.com
20th Oct 20227:00 amRNSLaunch of gift set collection for festive season
26th Sep 20227:00 amRNSProposed purchase of Cannaray Brands and Love CBD
23rd Sep 20225:49 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20225:47 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20225:42 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20227:00 amRNSCellular Goods now shipping products to the USA
23rd Sep 20227:00 amRNSCellular Goods now shipping products to the USA
21st Sep 20222:06 pmRNSSecond Price Monitoring Extn
21st Sep 20222:00 pmRNSPrice Monitoring Extension
21st Sep 20227:00 amRNSLaunch of three new skincare products
6th Sep 20227:00 amRNSPublication of new white paper
17th Aug 20227:00 amRNSGrant of Share Options
16th Aug 20227:00 amRNSAppointment of new Chief Financial Officer
5th Aug 20224:40 pmRNSSecond Price Monitoring Extn
5th Aug 20224:35 pmRNSPrice Monitoring Extension
4th Aug 20229:05 amRNSSecond Price Monitoring Extn
4th Aug 20229:00 amRNSPrice Monitoring Extension
3rd Aug 20224:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
3rd Aug 20229:05 amRNSSecond Price Monitoring Extn
3rd Aug 20229:00 amRNSPrice Monitoring Extension
2nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
2nd Aug 202211:05 amRNSSecond Price Monitoring Extn
2nd Aug 202211:00 amRNSPrice Monitoring Extension
1st Aug 20222:00 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSUpdate on marketing initiatives and YouGov survey
11th Jul 20227:00 amRNSLaunch of minis
20th Jun 20227:00 amRNSLaunch of CBG and CBD petition
30th May 20227:00 amRNSInterim results
20th May 20227:00 amRNSTR-1: Standard notification of major holdings
20th May 20227:00 amRNSTR-1: Standard notification of major holdings
16th May 20222:05 pmRNSSecond Price Monitoring Extn
16th May 20222:00 pmRNSPrice Monitoring Extension
12th May 20227:00 amRNSBoard changes
28th Apr 20227:00 amRNSInvestor presentation
28th Apr 20227:00 amRNSFirst patent application filed
22nd Apr 20226:04 pmRNSUpdate on ingestibles product range
22nd Apr 20227:00 amRNSWhite paper on lab-produced cannabinoids
13th Apr 20227:00 amRNSUpdate on ingestibles product range
11th Apr 20227:00 amRNSUpdate on ingestibles products
7th Apr 202210:24 amRNSTR-1: Standard notification of major holdings
1st Apr 20222:05 pmRNSSecond Price Monitoring Extn
1st Apr 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.